iShares Biotechnology ETF
906 hedge funds and large institutions have $7B invested in iShares Biotechnology ETF in 2026 Q1 according to their latest regulatory filings, with 66 funds opening new positions, 268 increasing their positions, 282 reducing their positions, and 93 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
more capital invested
Capital invested by funds: $ → $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
29% less first-time investments, than exits
New positions opened: 66 | Existing positions closed: 93
33% less funds holding in top 10
Funds holding in top 10: 12 → 8 (-4)
47% less call options, than puts
Call options by funds: $102M | Put options by funds: $193M
Holders
906
Holding in Top 10
8
Calls
$102M
Puts
$193M
Top Buyers
| 1 | +$361M | |
| 2 | +$121M | |
| 3 | +$94M | |
| 4 |
D.E. Shaw & Co
New York
|
+$59.8M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$50.6M |
Top Sellers
| 1 | -$157M | |
| 2 | -$97.5M | |
| 3 | -$73.6M | |
| 4 |
LPL Financial
San Diego,
California
|
-$45.8M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$41.5M |
